No Data
Celon Pharmaceuticals (688163.SH): Temporary suspension of clinical research on AnimaMab monoclonal antibody and recognition of long-term private equity impairment provision of 14.1448 million yuan.
Cellon (688163.SH) announced that its joint venture company, shanghai Sanyuan Biotechnology Co., Ltd. (sim...
Celon Pharma (688163.SH): has carried out research and development on new drugs for anti-snake venom serum, as well as a new series of products for rapid snake venom detection assays.
On November 13, Gelonghui reported that Sailun Biotech (688163.SH) stated on the interactive platform that the company has conducted research and development planning for new snake venom antivenom drugs and new products for rapid snake venom diagnosis based on years of accumulated research on snake venom toxins, technological advantages, and ongoing investment, with some projects already in the clinical research stage.
Syren Biotech: third quarter report 2024
Selon Biotechnology (688163.SH): net income in the first three quarters was 62.9475 million yuan, a year-on-year increase of 23.92%.
Gelonghui October 25th news: Selon Bio (688163.SH) released its third-quarter report, with revenue of 0.173 billion yuan for the first three quarters, a year-on-year increase of 4.31%, net income of 62.9475 million yuan, a year-on-year increase of 23.92%, non-net profit of 50.32 million yuan, a year-on-year increase of 30.93%, and basic earnings per share of 0.58 yuan.
Cellon (688163.SH) released its performance for the first three quarters, with a net income of 62.9475 million yuan, a year-on-year increase of 23.92%.
Cellon (688163.SH) released the third quarter report for the first three quarters of 2024, during which the company achieved revenue...
Shanghai Serum Bio-Technology Co., Ltd.'s (SHSE:688163) 44% Price Boost Is Out Of Tune With Earnings
Is Shanghai Serum Bio-Technology Co., Ltd.'s (SHSE:688163) Stock On A Downtrend As A Result Of Its Poor Financials?No Data
No Data
